GeneMedi's GPCR portfolio for GPCR targeting drug discovery and mechanism of action (MOA) research.

GeneMedi’s GPCR products are ligands, agonists and antagonists that are specific to bind to their target and thus are useful for target validation and drug discovery research. GPCRs are integral membrane proteins that modulate many physiological functions such as neuronal transmission, endocrine communication and immune defence. It is the largest family of membrane receptors in humans and is thus an important focus of drug discovery in the pharmaceutical industry. GPCRs are divided into five types according to their evolutionary relatedness: rhodopsin like, secretin like, metabotropic glutamate, pheromone and cAMP receptor. All family of GPCR has several proteins that are of significance and have their individual roles to play and their uses in the therapy.

For example, the rhodopsin-like family of GPCRs comprises of adrenergic, dopamine and serotonin receptors which are involved in the regulation of cardiovascular system, mood disorders and sleep-wake cycle respectively. Secretin-coupled family of GPCRs comprises of vasopressin, opioid and calcitonin receptors that are involved in water and electrolyte regulation, pain and calcium regulation respectively. GPCRs and their associated signaling pathways have been targeted in several ways which have made them useful in diagnosis and treatment. GPCRs are implicated in the development of many diseases, including cancer, diabetes and cardiovascular diseases and are, therefore, potential targets for drug intervention. Some of the-drugs include beta-blockers, angiotensin receptor blockers and anti histamines which are known to act on GPCRs and have been prescribed for different diseases. Also, some of the GPCRs can be employed for the diagnosis of specific diseases. For instance, GPCRs that are overexpressed have been associated with cancer and its progression and the level of these receptors can be used for the diagnosis and prediction of cancer.

GPCRs are a valuable and a rather diverse group of targets for medication and have a high possibility of being used in drug development. Due to their multicast signaling and roles, they offer multiple targets for targeted therapy and individualized treatment. GeneMedi has a range of benchmark antibodies for GPCR research applications such as ELISA, affinity binding assays, drug discovery, and MOA research. Pre-used monoclonal antibodies developed by us are produced from mammalian cell lines to provide high quality and reliability, and are suitable for use in cell culture, development of assays, animal models and PK/PD model for biological drug discovery.

Q&A

Q1. What GPCRs does GeneMedi offer?
A1: GeneMedi’s GPCR library comprises of ligands, agonists and antagonists which are very specific in their binding and are therefore suitable for drug screening and target identification.

Q2. What are GPCRs?
A2: GPCRs are play crucial role in the regulation of many physiological functions including hormones, neurotransmitters and immune systems are transmembrane proteins. These are the biggest family of membrane receptors in human beings.

Q3. How are GPCRs classified?
It is divided into five families based on the phylogenetic classification of the GPCRs which include Rhodopsin-like, Secretin-like, Metabotropic Glutamate, Fungal Pheromone, and cAMP receptor family.

Q4. What does GPCRs have to do with therapy?
A4: GPCRs have several therapeutic roles, for example in the control of the cardiovascular system, in pain control, in the regulation of fluids, and in calcium homeostasis. They are also associated with diseases including cancer, diabetes, cardiovascular diseases and are thus potential drug targets.

Q5. What are the products that GeneMedi provides for GPCR related study?
A5: GeneMedi offers GPCR quality benchmark antibodies for GPCR research and other applications such as ELISA, affinity binding, drug screening and optimizing mechanisms of action.